# Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

> **NCT06005324** · PHASE1 · RECRUITING · sponsor: **University of Chicago** · enrollment: 36 (estimated)

## Conditions studied

- HPV-Negative Squamous Cell Carcinoma

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin
- **DRUG:** Cetuximab
- **RADIATION:** Standard Dose Radiation
- **RADIATION:** Low Dose Radiation
- **DRUG:** Cisplatin
- **DRUG:** TFHX Regimen

## Key facts

- **NCT ID:** NCT06005324
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-18
- **Primary completion:** 2026-06
- **Final completion:** 2026-12
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06005324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06005324, "Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06005324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*